25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Eloxx Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Eloxx Pharmaceuticals Inc together

I guess you are interested in Eloxx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eloxx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eloxx Pharmaceuticals Inc

I send you an email if I find something interesting about Eloxx Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Eloxx Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Eloxx Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$-3.39
Expected worth in 1 year
$-45.44
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-42.05
Return On Investment
-42,048,870.8%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0 - $0.0002
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Eloxx Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-148.34 - $-15.62
Total Value Per Share
$-151.73 - $-19.01

2.2. Growth of Eloxx Pharmaceuticals Inc (5 min.)




Is Eloxx Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$10.6m$22.3m-$33m-310.0%

How much money is Eloxx Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$36m-$66.7m$30.6m85.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Eloxx Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Eloxx Pharmaceuticals Inc?

Welcome investor! Eloxx Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Eloxx Pharmaceuticals Inc.

First you should know what it really means to hold a share of Eloxx Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Eloxx Pharmaceuticals Inc is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eloxx Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eloxx Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-3.39. Based on the TTM, the Book Value Change Per Share is $-10.51 per quarter. Based on the YOY, the Book Value Change Per Share is $4.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eloxx Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-11.47-11,473,282.0%-11.47-11,473,282.0%-21.23-21,227,719.1%-14.98-14,979,242.2%-9.90-9,900,051.3%
Usd Book Value Change Per Share-10.51-10,512,217.7%-10.51-10,512,217.7%4.014,010,001.9%-0.73-733,679.6%-0.45-448,974.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.46461,285.4%
Usd Total Gains Per Share-10.51-10,512,217.7%-10.51-10,512,217.7%4.014,010,001.9%-0.73-733,679.6%0.0112,310.7%
Usd Price Per Share1.82-1.82-0.71-5.18-4.12-
Price to Earnings Ratio-0.16--0.16--0.03--0.36--0.46-
Price-to-Total Gains Ratio-0.17--0.17-0.18--0.61-4.68-
Price to Book Ratio-0.54--0.54-0.10-0.47-3.65-
Price-to-Total Gains Ratio-0.17--0.17-0.18--0.61-4.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-10.51-0.73
Usd Total Gains Per Share-10.51-0.73
Gains per Quarter (10000000 shares)-105,122,177.01-7,336,796.26
Gains per Year (10000000 shares)-420,488,708.05-29,347,185.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-420488708-4204887180-29347185-29347195
20-840977416-8409774260-58694370-58694380
30-1261466124-12614661340-88041555-88041565
40-1681954832-16819548420-117388740-117388750
50-2102443540-21024435500-146735925-146735935
60-2522932248-25229322580-176083110-176083120
70-2943420956-29434209660-205430295-205430305
80-3363909664-33639096740-234777480-234777490
90-3784398372-37843983820-264124665-264124675
100-4204887081-42048870900-293471850-293471860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.025.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%11.014.00.044.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%2.00.023.08.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%12.013.00.048.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eloxx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---10.512-10.5120%4.010-362%-0.734-93%-0.449-96%
Book Value Per Share---3.391-3.3910%7.121-148%6.402-153%4.758-171%
Current Ratio--0.8720.8720%4.368-80%3.841-77%3.182-73%
Debt To Asset Ratio--1.5051.5050%0.504+198%0.635+137%0.555+171%
Debt To Equity Ratio----0%1.017-100%0.683-100%1.183-100%
Dividend Per Share----0%-0%-0%0.461-100%
Eps---11.473-11.4730%-21.228+85%-14.979+31%-9.900-14%
Free Cash Flow Per Share---10.152-10.1520%-11.163+10%-10.575+4%-6.023-41%
Free Cash Flow To Equity Per Share---7.348-7.3480%4.994-247%-0.449-94%-0.329-96%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---15.623--------
Intrinsic Value_10Y_min---148.343--------
Intrinsic Value_1Y_max---5.074--------
Intrinsic Value_1Y_min---11.776--------
Intrinsic Value_3Y_max---12.571--------
Intrinsic Value_3Y_min---38.267--------
Intrinsic Value_5Y_max---16.845--------
Intrinsic Value_5Y_min---67.717--------
Market Cap314.339-1819900%5720969.8005720969.8000%2219862.018+158%16267797.664-65%12965037.791-56%
Net Profit Margin----0%-0%-0%-50.4570%
Operating Margin----0%-0%-0%-26.6790%
Operating Ratio----0%-0%-0%26.979-100%
Pb Ratio0.000+100%-0.537-0.5370%0.099-641%0.472-214%3.651-115%
Pe Ratio0.000+100%-0.159-0.1590%-0.033-79%-0.362+128%-0.456+188%
Price Per Share0.000-1819900%1.8201.8200%0.706+158%5.175-65%4.125-56%
Price To Free Cash Flow Ratio0.000+100%-0.179-0.1790%-0.063-65%-0.494+175%-2.053+1045%
Price To Total Gains Ratio0.000+100%-0.173-0.1730%0.176-198%-0.605+250%4.681-104%
Quick Ratio--0.8320.8320%4.246-80%4.289-81%3.468-76%
Return On Assets---1.707-1.7070%-1.478-13%-1.262-26%-1.026-40%
Return On Equity----0%-2.9810%-1.7730%-2.0760%
Total Gains Per Share---10.512-10.5120%4.010-362%-0.734-93%0.012-85491%
Usd Book Value---10660000.000-10660000.0000%22384000.000-148%20125400.000-153%14955965.400-171%
Usd Book Value Change Per Share---10.512-10.5120%4.010-362%-0.734-93%-0.449-96%
Usd Book Value Per Share---3.391-3.3910%7.121-148%6.402-153%4.758-171%
Usd Dividend Per Share----0%-0%-0%0.461-100%
Usd Eps---11.473-11.4730%-21.228+85%-14.979+31%-9.900-14%
Usd Free Cash Flow---31911000.000-31911000.0000%-35090000.000+10%-33240000.000+4%-18933563.500-41%
Usd Free Cash Flow Per Share---10.152-10.1520%-11.163+10%-10.575+4%-6.023-41%
Usd Free Cash Flow To Equity Per Share---7.348-7.3480%4.994-247%-0.449-94%-0.329-96%
Usd Market Cap314.339-1819900%5720969.8005720969.8000%2219862.018+158%16267797.664-65%12965037.791-56%
Usd Price Per Share0.000-1819900%1.8201.8200%0.706+158%5.175-65%4.125-56%
Usd Profit---36065000.000-36065000.0000%-66727000.000+85%-47085600.000+31%-28290385.300-22%
Usd Revenue----0%-0%-0%35000.000-100%
Usd Total Gains Per Share---10.512-10.5120%4.010-362%-0.734-93%0.012-85491%
 EOD+2 -6MRQTTM+0 -0YOY+13 -155Y+10 -1810Y+4 -28

3.3 Fundamental Score

Let's check the fundamental score of Eloxx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.832
Current Ratio (MRQ)Greater than10.872
Debt to Asset Ratio (MRQ)Less than11.505
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.707
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Eloxx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.836
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.300
Ma 100Greater thanMa 2000.576
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-01 02:38:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Eloxx Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-5,045.7%+5,045.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--124.9%+124.9%
TTM--208.9%+208.9%
YOY--207.8%+207.8%
5Y--351.9%+351.9%
10Y-5,045.7%-473.1%-4,572.6%
4.3.1.2. Return on Assets

Shows how efficient Eloxx Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • -170.7% Return on Assets means that Eloxx Pharmaceuticals Inc generated $-1.71 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is -170.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -170.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-170.7%TTM-170.7%0.0%
TTM-170.7%YOY-147.8%-22.9%
TTM-170.7%5Y-126.2%-44.6%
5Y-126.2%10Y-102.6%-23.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-170.7%-10.7%-160.0%
TTM-170.7%-11.7%-159.0%
YOY-147.8%-11.2%-136.6%
5Y-126.2%-12.6%-113.6%
10Y-102.6%-14.4%-88.2%
4.3.1.3. Return on Equity

Shows how efficient Eloxx Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Eloxx Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-298.1%+298.1%
TTM-5Y-177.3%+177.3%
5Y-177.3%10Y-207.6%+30.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.8%+13.8%
TTM--15.8%+15.8%
YOY-298.1%-13.6%-284.5%
5Y-177.3%-18.6%-158.7%
10Y-207.6%-19.1%-188.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eloxx Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Eloxx Pharmaceuticals Inc is operating .

  • Measures how much profit Eloxx Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,667.9%+2,667.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM--304.6%+304.6%
YOY--223.5%+223.5%
5Y--389.5%+389.5%
10Y-2,667.9%-497.7%-2,170.2%
4.3.2.2. Operating Ratio

Measures how efficient Eloxx Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y26.979-26.979
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.760-2.760
TTM-3.393-3.393
YOY-3.299-3.299
5Y-4.814-4.814
10Y26.9796.536+20.443
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eloxx Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Eloxx Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.87 means the company has $0.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.872. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.872. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.872TTM0.8720.000
TTM0.872YOY4.368-3.496
TTM0.8725Y3.841-2.970
5Y3.84110Y3.182+0.660
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8723.709-2.837
TTM0.8723.886-3.014
YOY4.3684.684-0.316
5Y3.8415.946-2.105
10Y3.1826.274-3.092
4.4.3.2. Quick Ratio

Measures if Eloxx Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.83 means the company can pay off $0.83 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.832. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.832. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.832TTM0.8320.000
TTM0.832YOY4.246-3.414
TTM0.8325Y4.289-3.457
5Y4.28910Y3.468+0.821
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8323.199-2.367
TTM0.8323.497-2.665
YOY4.2464.549-0.303
5Y4.2895.897-1.608
10Y3.4686.437-2.969
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eloxx Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Eloxx Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eloxx Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.50 means that Eloxx Pharmaceuticals Inc assets are financed with 150.5% credit (debt) and the remaining percentage (100% - 150.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 1.505. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.505. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.505TTM1.5050.000
TTM1.505YOY0.504+1.001
TTM1.5055Y0.635+0.870
5Y0.63510Y0.555+0.080
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5050.350+1.155
TTM1.5050.347+1.158
YOY0.5040.312+0.192
5Y0.6350.365+0.270
10Y0.5550.382+0.173
4.5.4.2. Debt to Equity Ratio

Measures if Eloxx Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eloxx Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.017-1.017
TTM-5Y0.683-0.683
5Y0.68310Y1.183-0.500
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.437-0.437
YOY1.0170.374+0.643
5Y0.6830.450+0.233
10Y1.1830.493+0.690
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eloxx Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Eloxx Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.16 means the investor is paying $-0.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eloxx Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.159. Based on the earnings, the company is expensive. -2
  • The TTM is -0.159. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.159+0.159
MRQ-0.159TTM-0.1590.000
TTM-0.159YOY-0.033-0.125
TTM-0.1595Y-0.362+0.203
5Y-0.36210Y-0.456+0.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.225+2.225
MRQ-0.159-2.362+2.203
TTM-0.159-3.066+2.907
YOY-0.033-3.335+3.302
5Y-0.362-6.032+5.670
10Y-0.456-6.575+6.119
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eloxx Pharmaceuticals Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.179. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.179. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.179+0.179
MRQ-0.179TTM-0.1790.000
TTM-0.179YOY-0.063-0.116
TTM-0.1795Y-0.494+0.314
5Y-0.49410Y-2.053+1.559
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.073+3.073
MRQ-0.179-3.177+2.998
TTM-0.179-3.575+3.396
YOY-0.063-4.527+4.464
5Y-0.494-8.367+7.873
10Y-2.053-9.230+7.177
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Eloxx Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.54 means the investor is paying $-0.54 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eloxx Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is -0.537. Based on the equity, the company is expensive. -2
  • The TTM is -0.537. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.537+0.537
MRQ-0.537TTM-0.5370.000
TTM-0.537YOY0.099-0.636
TTM-0.5375Y0.472-1.009
5Y0.47210Y3.651-3.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0001.893-1.893
MRQ-0.5372.003-2.540
TTM-0.5372.302-2.839
YOY0.0992.390-2.291
5Y0.4723.666-3.194
10Y3.6514.354-0.703
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eloxx Pharmaceuticals Inc.

4.8.1. Institutions holding Eloxx Pharmaceuticals Inc

Institutions are holding 19.586% of the shares of Eloxx Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31MENORA MIVTACHIM HOLDINGS LIMITED1.66560.00055235500
2023-12-31Altshuler Shaham Ltd0.79920.00172512300
2023-12-31Clal Insurance Enterprises Holdings Ltd0.43030.00021352600
2023-12-31Meeder Asset Management Inc0.000501500
2023-12-31SILVERARC CAPITAL MANAGEMENT, LLC000-54075-100
2023-12-31Atom Investors LP000-10638-100
2023-12-31Royal Bank of Canada000-526-100
2023-12-31Wells Fargo & Co000-1172-100
2023-12-31Tower Research Capital LLC000-1830-100
2023-09-30NewSquare Capital, LLC000-1-100
2023-12-31UBS Group AG000-291-100
2023-12-31Group One Trading, LP000-4-100
2023-12-31Morgan Stanley - Brokerage Accounts000-79-100
2023-12-31Vanguard Group Inc000-20786-100
2023-12-31Geode Capital Management, LLC000-19588-100
2023-12-31JPMorgan Chase & Co000-1-100
2023-12-31Armistice Capital, LLC000-275000-100
2023-12-31American Financial Group Inc000-37000-100
2023-12-31BlackRock Inc000-8870-100
Total 2.89560.002491019-429861-472.3%

4.9.2. Funds holding Eloxx Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.23690.0003744600
2023-12-31NT Quality Small Cap Core0.00320.000110100
2023-12-31NT Quality SCC US Fund - L0.00320.000110100
Total 0.24330.0005764800.0%

5.3. Insider Transactions

Insiders are holding 5.981% of the shares of Eloxx Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-11-29Daniel E GeffkenBUY500000.72
2021-05-13Pontifax Management 4 G.p. (20BUY59259251.35
2021-05-13Rajesh B ParekhBUY24666661.35
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Total Stockholder Equity 42,911-6,69836,213-25,98310,23012,15422,384-33,044-10,660
Net Tangible Assets  42,911-6,69836,213-25,98310,23012,15422,384-33,044-10,660
Net Working Capital  42,5343,36845,902-29,84716,05517,47033,525-36,487-2,962



5.2. Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets21,123
Total Liabilities31,783
Total Stockholder Equity-10,660
 As reported
Total Liabilities 31,783
Total Stockholder Equity+ -10,660
Total Assets = 21,123

Assets

Total Assets21,123
Total Current Assets20,129
Long-term Assets994
Total Current Assets
Cash And Cash Equivalents 19,207
Other Current Assets 568
Total Current Assets  (as reported)20,129
Total Current Assets  (calculated)19,775
+/- 354
Long-term Assets
Property Plant Equipment 994
Long-term Assets  (as reported)994
Long-term Assets  (calculated)994
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities23,091
Long-term Liabilities8,692
Total Stockholder Equity-10,660
Total Current Liabilities
Short-term Debt 4,692
Short Long Term Debt 3,980
Accounts payable 3,020
Other Current Liabilities 2,844
Total Current Liabilities  (as reported)23,091
Total Current Liabilities  (calculated)14,536
+/- 8,555
Long-term Liabilities
Long term Debt 8,557
Capital Lease Obligations 847
Long-term Liabilities  (as reported)8,692
Long-term Liabilities  (calculated)9,404
+/- 712
Total Stockholder Equity
Common Stock22
Retained Earnings -274,388
Other Stockholders Equity 263,706
Total Stockholder Equity (as reported)-10,660
Total Stockholder Equity (calculated)-10,660
+/-0
Other
Capital Stock22
Cash and Short Term Investments 19,207
Common Stock Shares Outstanding 2,166
Current Deferred Revenue12,535
Liabilities and Stockholders Equity 21,123
Net Debt -5,823
Net Invested Capital 1,877
Net Tangible Assets -10,660
Net Working Capital -2,962
Property Plant and Equipment Gross 994
Short Long Term Debt Total 13,384



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-31
> Total Assets 
0
0
1,085
1,085
1,744
274
5,230
3,266
5,211
6,113
3,535
3,322
10,643
7,122
13,912
8,597
6,955
7,098
33,335
19,547
9,226
5,845
50,718
58,947
26,026
45,139
21,123
21,12345,13926,02658,94750,7185,8459,22619,54733,3357,0986,9558,59713,9127,12210,6433,3223,5356,1135,2113,2665,2302741,7441,0851,08500
   > Total Current Assets 
0
0
959
959
1,565
30
3,802
2,605
4,230
4,390
1,308
763
6,358
2,592
9,331
5,056
3,550
3,522
7,224
3,730
983
284
50,341
57,709
25,893
43,480
20,129
20,12943,48025,89357,70950,3412849833,7307,2243,5223,5505,0569,3312,5926,3587631,3084,3904,2302,6053,802301,56595995900
       Cash And Cash Equivalents 
0
0
947
947
1,556
14
799
320
186
292
318
408
5,677
381
8,026
3,610
2,001
1,602
6,111
3,335
811
33
48,606
22,493
24,668
42,268
19,207
19,20742,26824,66822,49348,606338113,3356,1111,6022,0013,6108,0263815,677408318292186320799141,55694794700
       Short-term Investments 
0
0
0
0
0
2,872
2,872
2,099
3,950
3,942
850
250
500
1,050
0
0
0
0
0
0
38
102
0
33,783
0
0
0
00033,7830102380000001,0505002508503,9423,9502,0992,8722,87200000
       Net Receivables 
0
0
0
0
0
75
75
0
0
0
0
0
0
0
0
0
0
43
43
350
826
88
20
26
0
0
0
00026208882635043430000000000757500000
       Other Current Assets 
0
0
13
13
9
16
56
186
94
157
13
41
181
1,161
1,305
1,446
1,549
1,919
1,070
395
172
251
1,735
1,433
1,225
1,212
568
5681,2121,2251,4331,7352511723951,0701,9191,5491,4461,3051,16118141131579418656169131300
   > Long-term Assets 
0
0
126
126
179
244
1,428
661
981
1,723
2,227
2,559
4,285
4,530
4,581
3,541
3,405
3,576
26,110
15,818
8,243
5,561
377
1,238
133
1,659
994
9941,6591331,2383775,5618,24315,81826,1103,5763,4053,5414,5814,5304,2852,5592,2271,7239816611,42824417912612600
       Property Plant Equipment 
0
0
72
72
71
79
80
75
52
30
10
8
5
6
5
4
6
5
223
186
93
51
248
1,125
133
1,659
994
9941,6591331,1252485193186223564565810305275807971727200
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,881,114
0
0
0
13,903
13,903
5,781
0
0
0
0
0
0
0
00000005,78113,90313,903000-3,881,1140000000000000
       Intangible Assets 
0
0
0
97
97
158
348
579
922
1,438
2,210
2,544
3,214
3,885
4,569
3,525
3,394
3,566
11,979
9,800
8,100
5,500
0
0
0
0
0
000005,5008,1009,80011,9793,5663,3943,5254,5693,8853,2142,5442,2101,4389225793481589797000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
51
10
0
129
113
451
0
0
00451113129010510000000000000000000
> Total Liabilities 
4
4
3
173
225
480
445
409
480
523
583
632
807
1,455
5,931
4,079
3,502
3,312
5,845
7,323
4,665
4,974
7,807
22,734
16,247
22,755
31,783
31,78322,75516,24722,7347,8074,9744,6657,3235,8453,3123,5024,0795,9311,455807632583523480409445480225173344
   > Total Current Liabilities 
4
4
3
173
225
435
377
319
390
431
449
503
684
1,333
3,329
3,268
3,163
3,212
1,825
779
369
2,774
7,807
11,807
9,838
9,955
23,091
23,0919,9559,83811,8077,8072,7743697791,8253,2123,1633,2683,3291,333684503449431390319377435225173344
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,195
2,195
2,199
2,199
2,187
2,502
957
407
407
0
4,835
5,628
657
4,692
4,6926575,6284,83504074079572,5022,1872,1992,1992,1952,1950000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
407
0
0
4,336
5,239
0
3,980
3,98005,2394,3360040700000000000000000000
       Accounts payable 
4
4
3
170
215
169
80
56
69
218
78
109
370
977
557
560
595
637
901
232
90
192
747
1,871
481
1,379
3,020
3,0201,3794811,8717471929023290163759556055797737010978218695680169215170344
       Other Current Liabilities 
0
0
3
3
11
266
296
263
288
180
330
377
314
356
577
510
370
388
924
546
279
2,175
6,938
4,655
3,691
4,196
2,844
2,8444,1963,6914,6556,9382,175279546924388370510577356314377330180288263296266113300
   > Long-term Liabilities 
0
4
3
170
215
46
68
90
90
92
134
129
123
122
2,602
811
339
100
4,020
6,544
4,296
2,200
747
10,927
5,239
12,800
8,692
8,69212,8005,23910,9277472,2004,2966,5444,0201003398112,6021221231291349290906846215170340
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,502
6,376
0
0
006,37610,50200000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,920
0
0
2,200
0
0
0
0
0
0
0000002,200003,92000000000000000000
> Total Stockholder Equity
-4
-4
-3
912
1,519
-207
4,786
2,857
4,731
5,590
2,952
2,690
9,836
5,668
7,981
4,517
3,453
3,786
27,490
12,225
4,561
871
42,911
36,213
10,230
22,384
-10,660
-10,66022,38410,23036,21342,9118714,56112,22527,4903,7863,4534,5177,9815,6689,8362,6902,9525,5904,7312,8574,786-2071,519912-3-4-4
   Common Stock
2
2
2
5
79
79
119
119
138
155
155
175
184
198
501
778
941
23
138
188
205
292
360
402
404
871
22
228714044023602922051881382394177850119818417515515513811911979795222
   Retained Earnings -274,388-238,323-171,596-137,019-86,145-121,824-115,630-107,183-88,280-74,426-67,440-60,748-50,841-35,950-30,223-25,622-22,370-19,055-12,575-9,497-7,430-5,491-3,614-1,169-37-26-26
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115,632
119,218
119,983
122,402
60,047
129,825
174,515
183,250
0
0
00183,250174,515129,82560,047122,402119,983119,218115,63200000000000000000
   Treasury Stock000-1,703-1,1290000000000000000000000
   Other Stockholders Equity 
21
21
32
2,077
5,234
5,470
12,158
12,234
17,168
24,490
25,167
28,136
39,875
41,420
58,321
64,488
69,952
78,189
115,632
119,381
120,240
122,402
128,900
172,812
9,826
259,836
263,706
263,706259,8369,826172,812128,900122,402120,240119,381115,63278,18969,95264,48858,32141,42039,87528,13625,16724,49017,16812,23412,1585,4705,2342,077322121



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-19,288
Operating Income-19,288-19,288
 
Operating Expense (+$)
Research Development10,373
Selling General Administrative8,915
Selling And Marketing Expenses-
Operating Expense19,28819,288
 
Net Interest Income (+$)
Interest Income386
Interest Expense-1,531
Other Finance Cost-0
Net Interest Income-1,145
 
Pretax Income (+$)
Operating Income-19,288
Net Interest Income-1,145
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-20,482-19,239
EBIT - interestExpense = -1,531
-20,482
-18,951
Interest Expense1,531
Earnings Before Interest and Taxes (EBIT)--18,951
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-20,482
Tax Provision--
Net Income From Continuing Ops-20,482-20,482
Net Income-20,482
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-491,145
 

Technical Analysis of Eloxx Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eloxx Pharmaceuticals Inc. The general trend of Eloxx Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eloxx Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eloxx Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0002 < 0.0002 < 0.0002.

The bearish price targets are: 0 > 0.

Tweet this
Eloxx Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eloxx Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eloxx Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eloxx Pharmaceuticals Inc. The current macd is -0.07293376.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eloxx Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eloxx Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eloxx Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eloxx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEloxx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eloxx Pharmaceuticals Inc. The current adx is 58.91.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Eloxx Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Eloxx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eloxx Pharmaceuticals Inc. The current sar is 0.49933607.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eloxx Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eloxx Pharmaceuticals Inc. The current rsi is 23.84. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Eloxx Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEloxx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eloxx Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eloxx Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eloxx Pharmaceuticals Inc Daily Stochastic Oscillator ChartEloxx Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eloxx Pharmaceuticals Inc. The current cci is -37.42604601.

Eloxx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEloxx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eloxx Pharmaceuticals Inc. The current cmo is -62.31980701.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eloxx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEloxx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eloxx Pharmaceuticals Inc. The current willr is -66.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Eloxx Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Eloxx Pharmaceuticals Inc Daily Williams %R ChartEloxx Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eloxx Pharmaceuticals Inc. The current atr is 0.05734502.

Eloxx Pharmaceuticals Inc Daily Average True Range (ATR) ChartEloxx Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eloxx Pharmaceuticals Inc. The current obv is 80,089,882.

Eloxx Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEloxx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eloxx Pharmaceuticals Inc. The current mfi is 54.45.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Eloxx Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEloxx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eloxx Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Eloxx Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eloxx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.836
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.300
Ma 100Greater thanMa 2000.576
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Eloxx Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Eloxx Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eloxx Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eloxx Pharmaceuticals Inc

I send you an email if I find something interesting about Eloxx Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eloxx Pharmaceuticals Inc.

Receive notifications about Eloxx Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.